首页> 外文期刊>Annals of Saudi medicine. >Expression of androgen receptor in invasive ductal breast carcinomas: a clinicopathological study from Jordan
【24h】

Expression of androgen receptor in invasive ductal breast carcinomas: a clinicopathological study from Jordan

机译:浸润性导管癌中雄激素受体的表达:约旦的临床病理研究

获取原文
           

摘要

BACKGROUND: The clinical relevance of androgen receptors (ARs) expressed in breast cancer cells and the suggested prognostic impact has been an area of active research. The prevalence rate of AR expression in breast cancer has never been reported among Jordanian patients. OBJECTIVE: Determine the expression rate of ARs among invasive ductal breast cancer cases of different stages and molecular subtypes. Also, analyze the relationship between AR expression and clinicopathologic and immunohistochemical criteria, and assess the impact of AR expression on survival. DESIGN: Retrospective medical record review. SETTING: Tertiary care hospital in Amman, Jordan. PATIENTS AND METHODS: Our study comprised only of cases of invasive ductal breast carcinoma of no special type among females from records during a 10-year period between 2006 and 2015. Immunohistochemical staining was considered positive if more than 10% of tumor nuclei showed positive staining. MAIN OUTCOME MEASURES: The expression rate of ARs and the association of the expression rate with the clinicopathologic features of invasive breast cancer. SAMPLE SIZE: 293. RESULTS: Immunohistochemical staining for AR revealed positive stain.ing in 180 (61.4%) cases, including approximately 50% of triple-negative breast cancer cases. AR positivity correlated with estrogen receptor (ER) status ( P =.007) and smaller T size ( P =.014). However, no significant association was found with any of the other variables. AR expression was positively associated with overall survival ( P =.022) in general and in ER-positive cases ( P =.012). However, in the multivariate Cox regression model, AR was not independently associated with survival. CONCLUSIONS: These results were consistent with international reports showing a significant relationship of AR expression with ER status. In addition, AR expression was significantly associated with smaller tumor size. Although AR status was not independently associated with survival, our data suggest AR is a good prognostic factor.
机译:背景:在乳腺癌细胞中表达的雄激素受体(ARs)具有临床意义,并提示其预后影响一直是积极研究的领域。从未有约旦患者报道乳腺癌中AR表达的患病率。目的:确定AR在不同阶段和分子亚型的浸润性导管癌病例中的表达率。此外,分析AR表达与临床病理和免疫组化标准之间的关系,并评估AR表达对生存的影响。设计:回顾性病历审查。地点:约旦安曼的三级医院。患者与方法:我们的研究仅包括2006年至2015年10年间记录的女性中无特殊类型浸润性导管癌的病例。如果超过10%的肿瘤细胞核呈阳性,则免疫组织化学染色被视为阳性。主要观察指标:ARs的表达率及其与浸润性乳腺癌临床病理特征的关系。样本大小:293。结果:AR的免疫组织化学染色显示180例(61.4%)病例呈阳性染色,其中约50%为三阴性乳腺癌病例。 AR阳性与雌激素受体(ER)状态(P = .007)和较小的T大小(P = .014)相关。但是,没有发现与任何其他变量有显着关联。在一般情况和ER阳性病例中,AR表达与总生存率呈正相关(P = .022)(P = .012)。但是,在多元Cox回归模型中,AR与生存率并不独立相关。结论:这些结果与国际报道一致,国际报道显示AR表达与ER状态之间存在显着关系。另外,AR表达与较小的肿瘤大小显着相关。尽管AR状态并非与生存独立相关,但我们的数据表明AR是良好的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号